Angiotensin II receptor antagonists: where do we stand?

Details

Serval ID
serval:BIB_16904
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Angiotensin II receptor antagonists: where do we stand?
Journal
IDrugs
Author(s)
Burnier M., Maillard M.
ISSN
1369-7056 (Print)
ISSN-L
1369-7056
Publication state
Published
Issued date
03/2000
Peer-reviewed
Oui
Volume
3
Number
3
Pages
304-309
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Losartan, the first angiotensin II receptor antagonist was introduced in 1994. Since then, five other antagonists have been launched for the management of hypertension. In recent years, numerous studies have demonstrated that angiotensin II antagonists are as effective as other antihypertensive agents but with a better tolerability profile. The challenge with these agents is now to demonstrate their potential benefits on morbidity and mortality, and several very large clinical trials are therefore running in hypertension, congestive heart failure and diabetic nephropathy. In addition, research is focusing intensively on defining the role of angiotensin AT2 receptors, and the potential benefits of combining ACE inhibitors and angiotensin II antagonists.
Pubmed
Create date
19/11/2007 13:10
Last modification date
10/09/2019 6:26
Usage data